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Chapter 2
Improvement in Early Diagnosis and






Are Patients with Non-ST Elevation Myocardial Infarction
Undertreated? 
Saman Rasoul, Jan Paul Ottervanger, Jan-Henk E Dambrink, Menko-Jan de
Boer, Jan CA Hoorntje, AT Marcel Gosselink, Felix Zijlstra, Harry
Suryapranata, Arnoud WJ van ‘t Hof
BMC Cardiovasc Disord, In press




The worse prognosis in patients without ST-elevation (non-STEMI) as compared
to patients with ST-elevation myocardial infarction (STEMI), may be due to
treatment differences. We aimed to evaluate the differences in characteristics,
treatment and outcome in patients with non-STEMI versus patients with STEMI in
an unselected population.
Methods
Individual patient data from all patients in our hospital with a discharge diagnosis
of myocardial infarction (MI) between January 2001 and January 2002 were
evaluated. Follow-up data were obtained until December 2004.  Patients were
categorized according to the presenting electrocardiogram into non-STEMI or
STEMI.
Results
A total of 824 patients were discharged with a diagnosis of MI, 29% with non-
STEMI and 71% with STEMI. Patients with non-STEMI were significantly older
and had a higher cardiovascular risk profile. They underwent less frequently
coronary angiography and revascularization and received less often clopidogrel
and ACE-inhibitor on discharge. Long-term mortality was significantly higher in
the non-STEMI patients as compared to STEMI patients, 20% vs. 12%,
respectively, p =0.006. However, multivariate analysis showed that age, diabetes,
previous myocardial infarction and not performing angiography (but not non-
STEMI presentation) were independent and significant predictors of long-term
mortality. 
Conclusion
In an unselected cohort of patients discharged with MI, there were significant
differences in baseline characteristics, and (invasive) treatment between STEMI
and non-STEMI. Long-term mortality was also different, but this was due to
differences in baseline characteristics and treatment. More aggressive treatment




Myocardial infarction (MI) is usually categorized into non-ST-elevation myocardial
infarction (non-STEMI) and ST-elevation myocardial infarction (STEMI). Patients
with STEMI should be treated immediately with reperfusion therapy by either
percutanous coronary intervention (PCI) or thrombolysis, if admitted within 12 h of
symptom onset [1-4]. Patients with non-STEMI should be stabilized medically and
high-risk patients should be scheduled for an early (within days) interventional
strategy [5,6]. 
A previous study has shown that in unselected patients, mortality was significantly
higher in the non-STEMI as compared to STEMI patients [7]. However, in that study
coronary angiography was only performed in 52%, only 70% of the eligible STEMI
patients were treated with reperfusion therapy and no information was available with
regard to the type of reperfusion therapy. The purpose of our study was to evaluate
the baseline characteristics, treatment and prognosis in an unselected consecutive
cohort of non-STEMI versus STEMI patients in a single high-volume centre.
Methods
Population 
From January 2001 to January 2002, individual patient data from all patients with
the discharge diagnosis of acute myocardial infarction (MI) at the Isala klinieken
(Zwolle, The Netherlands) were recorded.  To avoid double inclusion of patients,
only the first admission for MI during the study period was used. 
According to the presenting ECG, patients were categorized as non-STEMI or
STEMI. Patients were diagnosed with non-STEMI if they had ischemic chest pain
classified as Braunwald class 3 and the presence of at least 1 of the following
criteria: (new) ST depression of more than 1 mm in at least 2 ECG leads or a
positive biomarker (cardiac troponin T > 0.05 µg/L, or CK-MB elevation more than
upper limit of normal).  STEMI was defined as chest pain of > 30 minutes duration
and ECG changes with ST segment elevation of > 2 mm in at least 2 precordial
and > 1 mm in the limb leads.  
Data collection and follow-up
We collected the following variables from the patient files: age, gender, history of
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction
and discharge medication. Follow-up information was obtained from the patient's
general physician or by direct telephone interview with the patient. 
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Statistical analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean and categorical data as
percentage, unless otherwise denoted. The analysis of variance and the chi-
square test were appropriately used for continuous and categorical variables
respectively. Cox proportional hazard regression procedure was performed to
estimate the hazard ratio of mortality of the findings. Significant variables
analyzed are reported with their respective Hazard ratio (HR) and 95%
confidence intervals (CI). For all analyses, statistical significance was assumed
when the two tailed probability value was < 0.05.
Results
During the study period, 824 patients were discharged with a diagnosis of MI;
29% categorized as non-STEMI (N = 241) and 71% as STEMI (N= 583). 
Baseline characteristics  
Baseline characteristics are summarized in Table 1. Patients with non-STEMI
were significantly older, more often female, had more often hypertension or a
history of previous myocardial infarction. 
Table 1: Baseline characteristics 
STEMI non-STEMI P-value
Variable                                  (N = 583)                    (N = 241)                                
Age, mean ± SD 63 ± 12 67 ± 12 <0.001
Female gender, n (%) 150/582 (26%) 77/240 (32%) 0.07
Diabetes, n (%) 80/568 (14%) 37/234 (16%) 0.53
Hypertension, n (%) 199/529 (38%) 101/229 (44%) 0.09
Hyperlipidemia, n (%) 126/406 (31%) 76/207 (37%) 0.16
Smoking, n (%) 251/558 (45%) 70/232 (30%) <0.001
Previous MI, n (%)                 81/578 (14%)              45/233 (19%)              0.06     




Cardiac catheterization and percutaneous coronary intervention (PCI) were
significantly less often performed in non-STEMI patients (Table 2). Coronary artery
bypass grafting (CABG) was performed more often in the non-STEMI patients.  
Table 2: Treatment and outcome
                                                STEMI                                    non-STEMI                 P-value
CAG, n (%) 541/583 (93%) 189/241 (78%) <0.001
PCI, n (%) 481/583 (83%) 99/241(41%) <0.001
Thrombolysis, n (%) 9/583 (2 %) -
CABG, n (%) 20/583 (3%) 41/241 (17%) <0.001
Conservative, n (%) 69/583 (12%) 96/236 (40%) <0.001
Death, n (%)                           71/574 (12%)                          47/236 (20%)              0.006
CAG = coronary angiography, PCI= percutanous coronary intervention, CABG= coronary artery
bypass grafting. 
At discharge, non-STEMI patients less frequently received clopidogrel, ACE-
inhibitors or statins than STEMI patients.  Nitrates and calcium channel blockers
were prescribed more often in the non-STEMI patients. Aspirin and beta blockers
were prescribed equally in both groups (Table 3). 
Table 3: Discharge medication
                                               STEMI                                    non-STEMI              P-value
Aspirin, n (%) 472/552 (86%) 187/221 (85%) 0.75
Beta blocker, n (%) 484/553 (88%) 188/221 (85%) 0.36
Clopidogrel, n (%) 381/553 (69%) 91/227 (40%) <0.001
Statines, n (%) 356/552 (65%) 126/221 (57%) 0.052
ACE-i, n (%) 300/553 (54%) 87/221 (39%) <0.001
Nitrate 67/447 (15%) 65/221 (29%) <0.001
Calcium channel blocker        16/446 (4%)                            40/221 (18%)              <0.001
ACE-i: angiotensin converting enzyme inhibitor.
Outcome
At 3 year follow up, mortality was 20% in the non-STEMI and 12% in the STEMI
patients, P =0.006 (Figure 1). Univariate predictors of mortality in the non-STEMI
patients were age, diabetes, previous myocardial infarction and not performing
coronary angiography (CAG) (Table 4). The excess mortality could not be
attributed to the higher CABG rate in the non-STEMI. Mortality rate was 3/41 (7%)
vs. 2/20 (10%), P =0.65, in the non-STEMI and STEMI patients who underwent
CABG. 
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Figure 1: Mortality curves stratified according to MI category
Univariate predictors of mortality in the STEMI patients were age, diabetes,
previous myocardial infarction, hypertension, not smoking and not performing
CAG (Table 4).
Table 4: Univariate analysis; predictors of mortality 
           Non-STEMI      STEMI 
Variable                      OR       95% CI            P-value           OR       95% CI          P-value
Age 1.14 1.09-1.20 <0.001 1.10 1.08-1.14 <0.001
Female gender 0.85 0.43-1.68 0.64 0.58  0.33-1.02 0.06
Diabetes 4.64 2.21-10.15 <0.001 3.6 1.93-6.72 <0.001
Previous MI 4.42 2.12-9.21 <0.001 2.18 1.51-5.24 0.001
Hypertension 1.03 0.53-2.02 0.93 2.41 1.36-4.29 0.003
Smoking 0.58 0.26-1.30 0.19 0.39 0.21-0.74 0.004
No CAG                      19.43   8.90-42.4        <0.001             3.67     6.78-27.63      <0.001
MI= myocardial infarction
Cox proportional hazard Analysis
The following factors were included in the Cox-regression analysis: age, gender,
diabetes, previous MI, hypertension, smoking, non-STEMI (STEMI reference) and
not performing CAG. This analysis revealed that age, diabetes, previous MI and
not performing CAG were significantly associated with increased risk of mortality
(Table 5). 
Log rank P = 0.003
Non-STEMI
STEMI



















Table 5: Hazard ratios of mortality of the significant factors in the multivariate model
Variable                                              HR                   95% CI                        P-value
Age 1.06 1.04-1.10 <0.001 
Female gender 1.20 0.76-1.90 0.43
Diabetes 2.12 1.34-3.35 0.001
Previous MI 1.64 1.04-2.60 0.03
Hypertension 1.35 0.95-2.75 0.15
Smoking 1.54 0.89-2.05 0.13
Non-STEMI* 1.07 0.88-2.65 0.76
No CAG                                              3.55                 2.12-5.93                    <0.001
MI= myocardial infarction, * STEMI is reference group
Discussion
This study identifies important differences in patient characteristics and
management among patients discharged with the diagnosis of non-STEMI versus
STEMI in a cohort of unselected patients. The higher mortality of patients with
non-STEMI was due to differences in baseline characteristics and treatment. 
The ratio of STEMI/non-STEMI is higher in our study as compared to other
studies [7]. The is due to the fact that, STEMI patients are consisted of those who
are admitted primarily to our hospital, referred patients and those diagnosed by
paramedics of the ambulance and transported directly to our centre for primary
PCI. While, non-STEMI patients consisted only those admitted directly to our
hospital.
Our results are in accordance with a previous study [7], showing that non-STEMI
patients have higher risk profiles and are treated less often with guideline
recommended medication. The lower mortality rate in our study may be due to
differences in treatment, rates of coronary angiography and revascularisation
therapy that were higher in our study. The prognosis after MI, for both non-STEMI
and STEMI in our study is worse as compared to two previous registries: the Euro
Heart Survey of Acute Coronary Syndromes (EHS-ACS) and the Global Registry
of Acute Coronary Events (GRACE) [8,9]. Possibly, in both GRACE and EHS-
ACS, some high-risk patients may have been excluded. For example, patients
dying within 24 h of admission were excluded from GRACE. 
Furthermore, compared to our study, many large scale randomized trials have
reported lower mortality at one year follow up after MI [10-14]. The reason for this
difference in outcome may due to low external validity of these trials due to
numerous inclusion and exclusion criteria in these trials. Therefore, their results
can not be reasonably applied to patients in routine clinical practice [15].
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Nevertheless, large scale clinical trials provide the most reliable data on the
effects of treatment. Results of registries are suggested to be more externally
valid than randomized trials because they include all patients and are performed
in a real world setting [16-17].                                                                                                              
Reasons for different outcomes 
The fact that non-STEMI patients were older, had higher risk profiles, were more
often treated conservatively and less frequently received guideline recommended
medication at discharge, might possibly explain the difference in mortality rate.
These results are in accordance with a previous study, showing that an early
invasive management strategy is not utilized in many high-risk patients [18]. An
invasive strategy appears to be reserved for patients without significant co-
morbidities and with a lower risk of in-hospital mortality. However, in patients older
than 75 years of age, a routine early invasive strategy may significantly improve
clinical outcomes [19]. Finally, the fact that circumflex artery occlusions are more
likely to present as non-STEMI than as STEMI might contribute to the worse
outcome in non-STEMI patients [20]. 
Challenges to improve outcome
The outcomes in patients with acute coronary syndromes have improved over
time. This was associated with the use of antiplatelet and antithrombotic therapies
and the increased utilization of revascularization [21]. However, despite these
improvements non-STEMI patients may have worse outcome [22]. Other factors
than patient characteristics and treatment strategy that may account for worse
outcome in non STEMI are the fact that identification of MI is often delayed due to
lack of definitive ECG abnormalities and timing of cardiac troponin elevation
[23,24]. In addition, almost half of patients with non-STEMI have other symptoms
than chest pain at presentation, which may contribute to delayed diagnosis [25].
The question remains how we can further improve the outcome of patients with
non-STEMI. This may be achieved by a multifactorial approach; first, identifying
high risk patients, which can be done through a good clinical evaluation of
medical history, physical examination, electrocardiogram (ECG) and cardiac
biomarkers e.g. myoglobin, cardiac troponin and CK-MB [26,27]. Second, using
the TIMI Risk Score, a simple clinical score that may be used by the clinician at
the bedside for risk assessment and therapeutic decision-making, and may
improve patient management [28,29]. Third, an early invasive strategy may
improve outcome. Several clinical trials have shown the beneficial effect of this
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strategy, and this may be even greater when combined with early initiation of
glycoprotein IIb/IIIa inhibitors [18,22,30-32]. Finally, recent data from the
CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress
ADverse outcomes with Early implementation of the ACC/AHA guidelines)
demonstrated that guideline recommended medication is underused despite their
proven clinical benefit [33].Treating patients according to the current guidelines
[1,5] will improve prognosis after MI, as has been reported in recent studies [34-
36].  
Future trials
All the above mentioned trials have increased our knowledge with regard to how
we should treat high-risk patients with non-STEMI. However, very early
aggressive therapy in non-STEMI patients, as is performed in STEMI, remains a
field for further research. Additional studies are warranted to evaluate whether
immediate cardiac catheterization and reperfusion in high-risk non-STEMI
patients will further improve the outcome. 
Conclusions
This study shows important differences in baseline characteristics, treatment and
prognosis between non-STEMI and STEMI patients. A more invasive therapy and
guideline recommended treatment might further improve outcome after MI,
especially in the non-STEMI population.
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Abstract
Background: More than 10 years ago, survival benefit of primary percutaneous
coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) was
demonstrated in several randomised trials. Since then, primary PCI has been
implemented in routine daily practice and is in the guidelines the preferred
reperfusion therapy for patients with STEMI. However, results of randomised trials
may differ from those in daily practice, and the primary PCI procedure has
evolved. 
We aimed to assess time-dependent changes in baseline characteristics,
concomitant treatment and prognosis in patients with STEMI treated with primary
PCI. 
Methods and Results: Individual patient data from all 4732 patients admitted for
primary PCI for STEMI between 1994 and 2004 in our hospital were recorded.
Patient characteristics, concomitant treatment and one-year outcome were
evaluated. During the 11 years period, mean age and proportion of females were
increasing, whereas door to balloon time decreased. Stent implantation rates
increased from 2% to 84%. At discharge, prescription of aspirin, beta-blockers,
statins, and ADP receptor blockers increased significantly. From 1994 to 2004,
hospital stay shortened from 10.4 to 4.5 days P<0.001. Hospital and one-year
mortality decreased, from 6.7% to 1.4% and 9% to 4.9% (both P<0.001),
respectively.
Conclusions: Between 1994 and 2004, utilization of stents and recommended
pharmacotherapies increased remarkably. In-hospital stay and both hospital and
one-year mortality decreased significantly. 
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Introduction
Both European and American guidelines state that primary percutaneous coronary
intervention (PCI), if possible, is the preferred therapeutic option in patients with ST-
elevation myocardial infarction (STEMI) [1,2]. Primary PCI is defined as intervention
of the infarct related vessel within 12 h after the onset of symptoms, without prior
thrombolytic therapy [3]. It was already performed in 1979 [4], but in 1993 the first
randomized clinical trials showed superior efficacy and safety of primary PCI over
thrombolysis [5-7]. Since then, primary PCI has been implemented in clinical daily
practice, and became available for a broad range of patients.
Primary PCI continues to evolve and it has changed most radically with adjunctive
therapy- glycoprotein IIb/IIIa inhibitors [8], thienopyridines [9] and reliance on stent
implantation [10-12]. Furthermore, extensive use of aspirin, statins, beta-blockers and
the common use of angiotensin-converting enzyme inhibitors (ACE-i), may further
reduce morbidity and mortality [13-15].
After publication of the first randomized trials in 1993, primary PCI was implemented
in daily practice in our hospital, and since 1994 all patients with STEMI were treated
with primary PCI. So, we have the opportunity to assess time dependent changes in
baseline characteristics, concomitant treatment, and prognosis in patients with
STEMI, admitted for primary PCI.
Aim




From January 1994 to December 2004, individual patient data from all eligible
patients with admission diagnosis of STEMI admitted for primary PCI at the Isala
klinieken (Zwolle, the Netherlands) were prospectively recorded. To avoid double
inclusion of patients, only the first recorded admission for STEMI during the study
period was used. Patients were diagnosed with STEMI if they had chest pain of >
30 minutes' duration and ECG changes with ST segment elevation > 2 mm in at
least 2 precordial leads and > 1 mm in the limb leads. Before the primary PCI
procedure all the patients received intravenous aspirin and heparin [16].
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Data collection and follow-up
We collected the following variables from the patient files: age, gender, history of
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction
and discharge medication. Data were grouped according to the calendar year of
patient’s hospital admission. Follow-up information was obtained from the
patient's general physician or by direct telephone interview with the patient. Data
were grouped according to admission year and started from 01 January to 31
December. Study approval was obtained from the medical ethic committee of our
hospital.
Statistical Analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation and categorical data as percentage,
unless otherwise denoted. The analysis of variance and the Mantel-Haenszel chi-
square test were appropriately used for continuous and categorical variables
respectively. Binary logistic analysis was performed to evaluate the risk of
hospital mortality. To assess time-related changes in prognosis, patients were
categorized to the admission year, with 1994 as the reference year. Significant
variables analyzed are reported with their respective odd ratios and 95%
confidence intervals. Cox proportional-hazards regression models were used to
estimate hazard ratios of clinical variables with regard to major adverse cardiac
events (death, reinfarction or re PCI) at one year. For all analyses, statistical
significance was assumed when the two-tailed probability value was < 0.05.
Hospital stay was analysed only in non-referred patients.
Results 
Baseline characteristics 
From 1994 through 2004, a total of 4732 patients with STEMI were admitted for
primary PCI at our hospital. The annual number of the patients increased from
178 in 1994 to 633 in 2004 (Figure 1). Mean age of the patients was 61 (19-95)
years, 24% were female, 11% had a history of previous myocardial infarction and
11% diabetes mellitus. A total of 2045 of the patients (43.2%) were referred from
non-PCI performing referring centres. From 1994 to 2004, mean age of the patients
increased from 59.7 to 62.4 years and rate of patients ≥ 75 years old increased
significantly (Figure 2). 
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Figure 1: Annual number of patients admitted for primary PCI













































































































































































































































































































































































































































































































































































































































































































































The proportion of females rose from 20% to 27%. There was a reduction in the
rate of patients with previous myocardial infarction, anterior myocardial infarct
location and Killip class>2, but an increase in the rates of hypertension and
hypercholesterolemia. Ischemic time and patient delay remained unchanged,
while door to balloon time decreased significantly (Table 1).  
Treatment
From the 4732 patients, 4300 were treated with primary PCI (90.9%), 170
patients (3.6%) underwent coronary artery bypass graft surgery and 262 patients
(5.5%) were treated conservatively (Table 2). Among the patients underwent
primary PCI, there was a sharp rise in stent implantation, from less than 2% to
84% (Figure 3). During the study interval, post primary PCI Thrombolysis in
Myocardial Infarction (TIMI) 3 flow grade was achieved more frequently (Table 2). 
Table 2: treatment
Variables (%) 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 P-value
No.of patients 178 251 299 328 427 410 470 446 665 625 633
Treatment 0.73
PCI 91.6 90.8 90 88.1 90.9 94.4 91.3 91 89.6 90.1 91.8
CABG 3.4 3.6 3.3 4.6 4.4 2.9 3.4 3.4 4.1 4 2.7
Conservative 2.8 4.4 5.7 6.8 3.1 2.2 2.3 4.86 4.3 4.1 3.4
Stent 1.9 11.5 30.9 49.8 54.5 55.1 60.6 60.6 76.8 80.0 84.1 <0.001
Post-PCI TIMI 3 86.1 85.6 88.4 80.9 85.3 85.5 88.8 88.6 90.3 93.9 91.2 <0.001
Medication
Aspirin 78.8 81.3 84.7 83.6 86.6 90.3 88.1 88.3 95.4 93.8 93.8 <0.001
B-Blocker 72.2 71.7 73.1 81.7 77.4 84.6 82.7 87.4 87.9 88.2 92.5 <0.001
Calcium chan bl 17.2 10.5 9.3 7.6 3.9 4 3.6 3.4 3.5 5 3.5 <0.001
ADP inhibitor 0 0.5 25.4 9.8 28.2 28.5 53.1 67.8 85.3 87.8 89 <0.001
ACE-i 52.6 48.7 51.1 55.7 45.3 51.6 50.3 53.6 54.4 54.1 56.8 0.052
PCI: percutaneous coronary intervention    CABG: coronary artery bypass grafting, B-blocker: beta
blocker, Calcium chan bl: calcium channel clocker, ADP inhibitor: adenosine diphpsphate inhibitor,
ACE-i: angiotension converting inhibitors
Discharge prescriptions for cardiac medications also changed over time.
Prescriptions of aspirin, beta-blockers, statins, and ADP receptor blockers
increased significantly. There was a slight increase in the prescription of ACE-i
between 1994 and 2004, from 52.6% to 56.7%, p=0.052. In patients with anterior
and non-anterior myocardial infarction ACE-i prescription increased from 66.7% to
72.1%, p=0.14 respectively 30.5% to 42.4%, p=0.003. Prescription of calcium
channel blockers decreased significantly (Table 2; Figure 3). 
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Figure 3: Pharmacotherapy 
Outcome 
In hospital 
Duration of hospital stay in survivors decreased from 10.4 to 4.5 days, p<0.001,
(Figure 4). Rates of re-infarction decreased significantly, from 1.7% to 0.6%.
Hospital mortality declined from 1994 through 2004 from 6.1% to less than 1.5%
(Figure 5). In referred patients this decreased from 7% to 1.1%.
The cumulative incidence of major adverse cardiovascular events (death, re-
infarction or re-PCI) declined from 1994 through 2004 from 16.9% to 6.6%,
p=0.001. The unadjusted and adjusted (age, gender, previous MI, hypertension,
hypercholesterolemia, anterior myocardial infarct location and Killip class) odds
ratio of mortality from 1994 through 2004 was 0.85/year (95%CI: 0.81-0.90) and
0.85/year (0.80-0.91), respectively. Thus there was a mean decrease of 15% in
hospital mortality each year. 
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Figure 4: Hospital stay in non-referred and referred patients 
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One- year
During the study interval, mortality and reinfarction rates decreased significantly,
from 9% to 4.9%; p=0.002 and from 4.5% to 3.5%; p< 0.001, respectively. The
cumulative incidence of major adverse cardiovascular events (death, re-infarction
or re-PCI) decreased significantly between 1994 and 2004 (Figure 6). 
Figure 6: Major adverse outcome at one year
The unadjusted and adjusted (age, gender, previous MI, hypertension,
hypercholesterolemia, anterior myocardial infarct location and Killip class) odds
ratio of major adverse cardiac events from 1994 through 2004 was 0.93/year
(95%CI: 0.90-0.97) and 0.93/year (0.89-0.96), respectively.
Discussion 
This study presents 11 years of experience with primary percutaneous coronary
intervention for ST-elevation myocardial infarction. Rates of primary PCI and stent
implantation have increased considerably. Utilization of aspirin, beta-blockers,
statins and ADP receptor blockers increased also significantly. Despite increasing
age of the patients, there was a decrease in hospital stay and hospital mortality or
re-infarction. At one-year follow up there was also a decline in one-year mortality





















Primary percutaneous coronary intervention (PCI)
The superiority of primary PCI over thrombolysis has been well studied [5-
7,17,18]. Both European and American guidelines state that primary PCI is the
preferred therapeutic option in patents with STEMI admitted within 90 minutes
after diagnosis [1,2]. Because of the superior efficacy and safety of primary PCI
over thrombolysis, primary PCI has become routine daily clinical practice in our
center. Thrombolysis is no longer used in our hospital after 1994. Since then, all
eligible STEMI patients had immediate coronary angiography for revascularization
therapy. 
In the current study, the decline in hospital mortality from 1994 through 2004 may,
at least partially, due to the high volume in our centre. Several studies have
shown the relation between the volume of procedures and the outcome [19-21]. 
The use of stent implantation has increased from 2% to over 80% in our study.
Several randomized clinical trials have showed the association between stent use
in combination with primary angioplasty and outcome [10-12] although results
may be less clear [22]. 
Improved pharmacotherapy
The impact of pharmacotherapies on outcome after myocardial infarction has
been well studied. Medications that improve the outcome are aspirin, beta-
blockers, ACE-i, statins and ADP receptor blockers [9,13-15,23] whereas calcium
channel blockers seem to have deleterious effects [24]. Figure 3 shows that we
have incorporated these findings into daily practice. These trends are consistent
with other studies [25,25] showing increased prescription of guideline
recommended pharmacotherapies on discharge. 
 Improved outcome 
A significant decline in hospital stay and improved outcome was found. Results of
primary PCI changed only little (TIMI 3 flow post PCI increased from 86% to 91%)
and the major part of this favourable trend may be due to increased use of
pharmacotherapies after primary PCI. Furthermore, the lower incidence of
reinfarction can also partially explain the benefits in mortality observed in these
patients [27,28].
During the study period there were several changes in the baseline
characteristics. Prevalence of previous myocardial infarction, anterior myocardial
infarction or Killip class>2 decreased, whereas there was a significant increase of
the mean age, female proportion and particularly of patients ≥ 75 years old. This
reflects the change of our policy, nowadays accepting all (referred) patients with
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STEMI for primary PCI. After adjusting for these variables, however, our data
shows still improvement in both short-and long term outcome. These results are
consistent with recent data from the Euro Heart Survey, that showed an
improvement in both in-hospital and 30-day outcome after acute coronary
syndrome between 2000 and 2004 [25]. In addition, recently data from the
Register of Information and Knowledge about Swedish Heart Intensive Care
Admissions (RIKS-HIA) also showed improved outcome with primary PCI
between 1999 and 2004.29 
 
Future directions
In this study we show progress in primary PCI and concomitant medical treatment
for STEMI. Nevertheless, there are several other factors that in combination with
primary PCI may further improve the outcome of patients with STEMI. Among
these factors are proximal or distal protection devices to prevent distal
embolization, stem cell therapy in patients with anterior myocardial infarction and
implantable cardiac defibrillators in high-risk patients. Pre-hospital diagnosis and
therapy initiation in the ambulance before transportation and the effect of newer
anti-thrombotic agents e.g. bivaliridin are also a field of interest. Currently, there
are additional trials going on to address these issues. 
Limitations
The patient population included in this study are all consecutive patients who
were included in the prospective registry from 1994 through 2004. Although we
tried to register all patients with STEMI, it however, is not possible to include all
patients e.g. STEMI patients that are not referred because of atypical chest pain
or presented too late. 
The treatment strategy and outcome may differ in those not enrolled in this
registry. We had no data on the use of glycoprotein IIb/IIIa inhibitors. The use of
these agents in patients with STEMI appeared to improve coronary patency with
favourable trends for clinical outcome [8]. Another limitation is that we only have
data on all cause-mortality and not on cause specific death.  
Conclusions
These data show the 11 years experience of primary PCI in a high volume center.
It shows a decrease in hospital stay, increased utilization of effective
pharmacotherapies and improvements in clinical outcome despite increasing age
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of the patients. This analysis confirms the previous randomised trials,
demonstrating that primary PCI for STEMI is safe and highly effective in routine
daily practice. 
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Despite data showing that time to treatment is very important in ST elevation
myocardial infarct patients, unacceptable long delays to reperfusion remain
present in daily life practice. We sought to evaluate the feasibility and effect of
improving logistics by early infarct diagnosis in the ambulance and immediate
triage to a PCI center performed by paramedics only without interference of a
physician.
Methods
In the On-TIME (Ongoing Tirofiban In Myocardial infarction Evaluation) study, 209
patients were included after pre-hospital infarct diagnosis and triage in the
ambulance (Ambulance group, N=209). Infarct diagnosis was made by highly
trained paramedics with the help of a computerized ECG algorithm. The accuracy
of diagnosis, time to treatment, left ventricular function and clinical outcome were
compared with the patients who were diagnosed and triaged at a referral non-PCI
center (Referred group, N=258). Left ventricular function was assessed before
discharge using a nuclear technique. 
Results
Acute myocardial infarction was accurately diagnosed in 95% of patients in the
ambulance group as compared to 99% in the referred group (p=0.01). The
percentage of patients in whom pharmacologic pre-treatment (heparin, aspirin,
tirofiban or placebo) was initiated in the ambulance within 90 minutes after the
onset of symptoms was 59 % in the ambulance group vs. 43 % in the referred
group (p<0.01). A left ventricular ejection fraction (LVEF) of less than 40% was
present in 25 % in the ambulance group, as compared to 38 % in the referred
group (p=0.013). After multivariate analysis, ambulance triage was independently
associated with a LVEF > 40% and a favorable long term clinical outcome.
Conclusions
Early, pre-hospital infarct diagnosis, triage and therapy in the ambulance with
direct transportation to the nearest PCI center, performed by trained paramedics
only is feasible in 95% of patients. Ambulance triage resulted in earlier diagnosis
and initiation of therapy and was independently associated with a better left
ventricular function and clinical outcome, as compared to triage and




Primary coronary angioplasty has been shown to be a very effective reperfusion
modality in patients with ST elevation myocardial infarction [1,2], even when
additional transport is necessary to a PCI center [3]. However, time to reperfusion
is often considerably longer when the data from registries are reported instead of
the data from randomized trials. In a large registry in the USA, only 5% of patients
had a door to balloon time less than 60 minutes [4]. Although door to balloon
times decreased from 90 to 70 minutes in the most recent Euro Heart Survey
analysis on acute coronary syndromes [5], many patients still have unacceptable
long times to treatment.   Some of the delay might be prevented by pre-hospital
infarct diagnosis and triage, selecting patients who are candidates for primary
angioplasty who can immediately be transported to a PCI center. However, it is
unclear whether this can be reliably performed by paramedics without
interference of a physician.
This study evaluates the feasibility and benefit of pre-hospital infarct diagnosis
and triage in the ambulance by paramedics only and compares outcome with
triage at a referral non-PCI center. 
Patients and Methods
The design, in- and exclusion criteria and main findings of the On-TIME (Ongoing
Tirofiban In Myocardial infarction Evaluation) study have been described
previously [6]. In this study, 209 patients were included after pre-hospital infarct
diagnosis and triage in the ambulance (Ambulance group, N=209). The accuracy
of diagnosis, time to treatment, the quality of reperfusion, left ventricular function
and clinical outcome was compared with the patients who were diagnosed and
triaged at a referral non-PCI center (Referred group, N=258). The presence of an
ambulance equipped with 12-lead ECG diagnostic facilities determined whether a
patient was transported to a non-PCI center first or immediately referred to the
PCI center.
Emergency transportation was performed after a telephone call, done either by
the ambulance driver (ambulance group) or the referring physician (referred
group), with the aim to prepare the arrival of the patient directly at the
catheterization laboratory. Recruitment and randomization in the ambulance was
initiated only after a period of training in pre-hospital infarct diagnosis and care for
at least 6 months. All paramedics had at least 2 years of training at a (cardiac)
intensive care unit and worked strictly according to board certified protocols.
Computer diagnosis in the ambulance was made based upon a fixed algorithm,
which has been described previously [7,8]. Before transportation all patients
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received 500 mg of aspirin and 5.000 IU of unfractionated heparin intravenously
and study medication (tirofiban or placebo). Post PCI, all patients were treated
with clopidogrel (300 mg loading dose followed by 75 mg daily for one month),
aspirin, beta blockade, statin, and ACE inhibition.
Time from symptom onset to diagnosis was defined as the time from the onset of
symptoms to the time of the diagnostic ECG, either made in the ambulance or at
the non-PCI center. Total ischemic time was defined as the time from symptom-
onset to first balloon inflation.
All angiographic and electrocardiographic parameters were analyzed by an
independent core-lab (Diagram BV, Zwolle, the Netherlands) and scored by
observers who were unaware of randomization and outcome data. A correct
infarct diagnosis was defined as prolonged chest pain with typical evolutionary
electrocardiographic changes, coupled with an unstable coronary lesion on the
angiogram and a rise in CK of more than 3 times the upper limit of normal.
Prevented myocardial infarction was defined as a correct infarct diagnosis without
a rise in CK of more than 3 times the upper limit of normal. A false positive infarct
diagnosis was made in those patients who did not meet the criteria for a correct or
prevented myocardial infarction. Left ventricular ejection fraction (LVEF) was
assessed in the patients recruited in the Zwolle area only and was measured with
a radionuclide technique before discharge, as previously described (1). The data
on LVEF were gathered by a specialist in nuclear medicine, who was blinded to
the clinical data.   Clinical outcome, being the incidence of death or recurrent
myocardial infarction, was assessed at 1 year follow-up.
Statistical Analysis
Statistical analysis was performed with the SPSS 10.0 statistical package. All
non-continuous angiographic variables were analysed using the Chi-square test
or Fisher exact test. Continuous variables were analysed using analysis of
variance or Mann Whitney test. The continuous variables time from symptom
onset to diagnosis and total ischemic time were dichotomized, based upon the
median value (94 minutes and 188 minutes respectively). Key outcome
parameters were the percentage of patients with a correct infarct diagnosis, left
ventricular ejection fraction before discharge and the 1 year incidence of death or
recurrent myocardial infarction. Risk stratification was based upon the previously
described TIMI risk criteria (9). To assess independent predictors of left
ventricular function and clinical outcome, multivariate analysis was performed,
using stepwise logistic regression. All parameters which were significantly
different between the groups (gender and distance to the PCI center) and all
baseline characteristics associated with left ventricular function or clinical
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outcome with a p-value of 0.10 or less were entered into the model. The cutoff
value of 40% for determination of a poor left ventricular function was based upon
a value lower than the 25% percentile (38%).
Results
A correct infarct diagnosis was present in 95% of patients triaged by ambulance
personnel as compared to 99% triaged at a referral center (p=0.01). The 14
patients with a false positive infarct diagnosis either had severe aortic stenosis
(3), left ventricular hypertrophy with strain (1), previous myocardial infarction with
persistent ST elevation (2), atrial fibrillation with early repolarization (2),
pericarditis (2), gastro-intestinal disease (2) or other (2). 
Baseline characteristics of the ambulance and the referred group are described in
Table 1 and were not significantly different, except for gender and distance to the
PCI center (45 vs 24 km, p<0.001). The percentage of patients who were
diagnosed within 90 minutes or underwent balloon inflation within 3 hours after
the onset of symptoms was also different and significantly higher in patients after
triage in the ambulance (Table 1). Both initial perfusion of the infarct related
vessel and final myocardial perfusion as assessed by the myocardial blush grade
was better in the patients triaged in the ambulance (Table 1). 
Prevented myocardial infarction was present in 15% in the ambulance group and
in 10% in the referred group (p=0.08). Left ventricular ejection fraction was
measured before discharge in 318 of the 426 (75%) patients with a confirmed
diagnosis of acute myocardial infarction, recruited in the Zwolle area. The LVEF
was 46% ± 10 in the ambulance group as compared to 44% ± 11 in the referred
group (p=0.17). A left ventricular ejection fraction of less than 40% was present in
25% in the ambulance group, as compared to 38% in the referred group
(p=0.013).
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Table 1: Baseline, Electrocardiographic and Angiographic Characteristics 
Referred Ambu P-value
                                                            (N=258)                      (N=209)                                  
Baseline
Age ( yrs ± SD) 62 ± 11 61 ± 11 0.88
Male gender 77% 85% 0.03
Diabetes 9% 13% 0.17
Hypertension 29% 26% 0.37
Smoking* 66% 64% 0.68
Anterior MI 46% 46% 0.90
Previous MI 10% 7% 0.24
Previous CABG 1.6% 2.4% 0.52
Previous PCI 4.3% 5.8% 0.46
Killip class > 1† 16% 19% 0.39
TIMI risk score > 3‡ 42% 46% 0.38
SO to diagnosis < 90 min 43% 59% 0.001
Ischemic time < 3 hrs 29% 52% 0.001
Electrocardiographic
Cum. ST elevation (mm) 10 ± 7 11 ± 8 0.24
Cum. ST deviation (mm) 15 ± 9 15 ± 9 0.81
Angiographic
Single vessel disease 41% 49% 0.11
Pre PCI 
TIMI 2,3 35% 44% 0.04
Post PCI
TIMI 3 91% 91% 0.97
            MBG 3                                    47%                             59%                             0.02     
*current or previous smoking. †defined as systolic blood pressure < 100 mm Hg or heart rate > 100
/min. ‡TIMI risk score as described by Morrow et al (9). 
CABG = coronary artery bypass grafting. MBG = myocardial blush grade as previously defined (18).
PCI = percutaneous coronary intervention. SO = symptom onset. 
Discharge medication
Discharge medications are shown in Table 2. On discharge the vast majority of
patients received aspirin, beta-blocker, statin and clopidogrel.
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Table 2: Medication at 30 days follow-up
Referred Ambu P-value
                                                            (N=239)                      (N=202)                                   
Aspirin 93% 89% 0.17
Oral anticoagulation 10% 10% 0.90
Beta blocker 89% 84% 0.13
Calcium channel blockers 6% 4% 0.24
Nitrates 17% 15% 0.51
ACE inhibitor 53% 57% 0.43
Statin 88% 85% 0.33
Clopidogrel*                                        81%                             76%                             0.19              
* Use at discharge
Univariate and Multivariate analysis
Left ventricular function
Univariate predictors of a poor left ventricular function were male gender, anterior
infarct location, the presence of diabetes, an initial heart rate > 100 beats/min, a
TIMI risk score above 2 and non-ambulance triage. After multivariate analysis,
only male gender, anterior infarct location and non-ambulance triage were
independently associated with a poor left ventricular function (Table 3).
Clinical outcome
At 30 day follow-up, 1.0% of patients with a correct diagnosis of acute myocardial
infarction had died in the ambulance group as compared to 3.2% in the referred
patients (p=0.2). At one year follow-up, total mortality and the combined incidence
of death or recurrent myocardial infarction was significantly lower in the
ambulance group (2.1% vs. 6.0%, p=0.04 and 3.6% vs 10.5%, p=0.006
respectively). After multivariate analysis, ambulance triage remained an
independent predictor of survival free from death or myocardial infarction at one
year follow-up (Table 3).
Shift towards earlier diagnosis and treatment
56
Table 3: Predictors of left ventricular function and clinical outcome
Variables                                                                    OR                  95% CI                   P-value
Left Ventricular Ejection Fraction < 40%
Univariate
Male gender 1.8 0.9 - 3.6 0.08
Diabetes 2.1 1.0 – 4.4 0.04
Anterior infarct location 6.3 3.7 – 10.8 <0.01
Heart rate > 100 / min 3.1 1.0 – 9.3 0.03
TIMI risk score > 2 5.9 3.2 – 10.8 <0.01
Distance < 41 km 0.8 0.5 – 1.4 0.54
Ambulance triage 0.5 0.3 – 0.8 0.01
Single vessel disease 1.0 0.7 – 1.8 0.71
Multivariate
Male gender 2.6 1.2 - 5.5 0.02
Anterior infarct location 3.7 1.6 – 8.9 <0.01
Ambulance triage 0.4 0.2 – 0.8 0.01
Death or recurrent myocardial infarction at 1 year follow-up
Univariate
Age (per year) 1.05 1.0 – 1.1 0.02
Male Gender 1.8 0.6 – 5.2 0.29
Hypertension 2.7 1.3 – 5.5 0.01
Anterior infarct location 1.9 0.9 – 3.2 0.08
Heart rate > 100 / min 3.0 1.2 – 7.9 0.03
TIMI risk score > 2 2.2 1.1 – 4.5 0.03
Single vessel disease 0.4 0.2 – 0.9 0.03
Distance < 41 km 0.7 0.3 – 1.4 0.29
Ambulance triage 0.3 0.1 – 0.7 0.01
Multivariate
Ambulance triage 0.3 0.1 – 0.9 0.03
Hypertension 2.5 1.1 – 5.5 0.03
Single Vessel disease 0.4 0.2 – 1.0 0.05
Anterior infarct location                                              2.3                   1.0 – 5.3                     0.05
Discussion
This study showed that correct infarct diagnosis, triage and therapy can be
performed by highly trained paramedics only, without interference of a physician,
in 95% of patients. Furthermore, it shows that ambulance triage is an independent
predictor of a left ventricular ejection fraction of more than 40 % and a favorable
clinical outcome, as compared to triage at a referral non-PCI center. The
mechanism of the beneficial effect seems to be the combination of earlier
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diagnosis, earlier initiation of pharmacologic pre-treatment and a better initial and
final myocardial perfusion. It showed that further streamlining of logistics, in which
an unnecessary visit of a non-PCI center is prevented, saves time and is
associated with a better left ventricular function and clinical outcome. 
Pre-Hospital Care
The most recent version of the ACC/AHA guidelines for the treatment of patients
with ST elevation acute myocardial infarction state that primary angioplasty is the
preferred reperfusion strategy if it can be performed within 90 minutes after first
patient contact [10]. However, it was recently shown that only 5% of transferred
patients in the USA have a door-to balloon time of less than 90 minutes (4). Also
in Europe, every day door-to-balloon times are considerably longer than those
reported in randomized controlled trials [11]. This long delay prevents further
development of primary angioplasty programs, and is often stated as an excuse
for treating the patients with thrombolysis or a combined pharmaco-invasive
strategy, which so far, has not been supported by evidence from randomized
controlled trials. Many obstacles have been associated with the lack of
development of a pre-hospital diagnosis and care program of patients with an
acute myocardial infarction. The fear of a false positive infarct identification when
diagnosis is made without interference of a physician is one of them. This study
shows that the combination of trained paramedics together with a validated
computerized ECG algorhythm results in a correct diagnosis in 95% of cases. 
Mechanism of benefit
It is unlikely that the reduced total ischemic time alone may sufficiently explain the
beneficial effect on left ventricular function. The moment of time saving is
important: saving 30 minutes in the very early phase of myocardial infarction is
expected to result in a larger benefit as compared to a saving of 30 minutes later
on, the so called ‘Golden Hour’ of reperfusion therapy [12,13]. The majority of
patients triaged in the ambulance were diagnosed within 90 minutes and treated
within 180 minutes after the onset of symptoms. This very early diagnosis and
therapy is probably related to the better myocardial blush grade after PCI in this
group [14]. In addition, a pre-hospital diagnosis gives the opportunity for early
initiation of anti-thrombotic and anti-platelet pre-treatment during transportation.
Agents like aspirin, heparin and glycoprotein 2b/3a blockers have shown to
improve initial patency of the infarct related vessel [15,16]. The very early
initiation of these agents in the ambulance group might explain the higher initial
patency rate in this group, resulting in a higher rate of prevented myocardial
infarction and might contribute to the better left ventricular function and clinical
outcome of these patients. This study confirms previous findings from our group,
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which showed that extra transportation delay is associated with a worsening of
the left ventricular ejection fraction [17]. The difference in outcome cannot be
explained by a difference in medication after discharge as shown in Table 2.
Limitations
This study is a post-hoc analysis of patients recruited in the On-TIME trial and not
a randomized comparison between pre-hospital triage in the ambulance versus
triage at the referral center, however, randomization would be unethical, as this
would deliberately prolong time to treatment in one arm. The presence of an
ambulance equipped with 12-lead ECG diagnostic facilities determined whether a
patient was transported to a non-PCI center first or immediately referred to the
PCI center. In- and exclusion criteria were the same for both study groups.
However, multivariate analysis might correct differences in baseline
characteristics between the groups, although this statistical correction might not
overcome the problem of undetectable confounders and is less reliable in a
relatively small sized trial with a low incidence of the outcome parameter of
interest. Left ventricular ejection fraction was routinely performed at discharge in
the patients recruited in the Zwolle area only (pre-specified LVEF substudy).
Patient characteristics of these Zwolle patients however did not differ significantly
from the patients recruited at other PCI centers.
Conclusion
Pre-hospital infarct diagnosis, triage and therapy in the ambulance is feasible
without physician interference when performed by highly trained paramedics
using validated computerized ECG software in 95% of patients. In addition, it was
found that ambulance triage was an independent predictor of a left ventricular
function of more than 40% and was independently associated with a favourable
clinical outcome. Therefore, all efforts should be made to implement pre-hospital
infarct diagnosis, triage, and therapy in the care of patients with an acute
myocardial infarction, and to further improve cooperation with ambulance
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To compare dual versus triple antiplatelet pre-treatment in patients with non ST
elevation acute coronary syndrome (NSTE ACS) who were planned for early
catheterisation.
Methods and Results
 A total of 328 consecutive patients with NSTE ACS were included and were
randomised to pre-treatment with dual (N=166, aspirin, clopidogrel 600 mg) or
triple antiplatelet therapy (N=162, aspirin, clopidogrel 300 mg and tirofiban). The
primary end point was enzymatic infarct size, defined as cumulative LDH release
(LDHQ48). Initial TIMI flow of the culprit vessel was a pre-specified secondary end
point. Angiography was performed in 98% of patients at a median of 23 hours
after admission. Enzymatic infarct size (median, 25-75%) was 166 (60-349) IU/l in
the triple group compared to 193 (75-466) IU/l in the dual group (p=0.2). Initial
TIMI 3 flow of the culprit vessel was significantly more often observed after triple
antiplatelet therapy (67% vs. 47%, p=0.002). At 30 days follow-up, myocardial
infarction occurred in 46% of patients in the triple antiplatelet group, compared to
57% in the dual antiplatelet group, p=0.052. No significant difference in bleeding
was present.
Conclusion
This study showed that in patients with NSTE ACS, triple antiplatelet pre-
treatment was associated with a non-significant reduction in enzymatic infarct
size, a significantly better initial perfusion of the culprit vessel and a trend towards
a better survival without death or myocardial infarction. Further, large scale
studies should be performed to find whether the beneficial trend in favour of triple




Previous studies showed that glycoprotein IIb/IIIa blockers improve outcome in
high risk patients with non ST elevation acute coronary syndrome (NSTE ACS),
especially in those patients who undergo an early invasive strategy [1-3]. These
studies however, were performed without the routine co-administration of
clopidogrel. In the past few years, clopidogrel has been shown to be effective as
pre-treatment in patients undergoing angioplasty. These effects were shown both
in patients undergoing elective PCI [4] and in patients with NSTE ACS [5]. In
addition it was found that a loading dose of 600 mg was associated with faster
platelet aggregation inhibition, as compared to the regular 300 mg loading dose
[6]. In the ELISA-1 study, it was shown that a strategy of delayed angiography
with concomitant pre-treatment with tirofiban was associated with improved
angiographic outcomes and less initial enzyme release [7]. These brought us to
compare a dual anti-platelet strategy of aspirin and 600 mg of clopidogrel with a
triple anti-platelet strategy of aspirin, clopidogrel 300 mg and the glycoprotein
IIb/IIIa blocker tirofiban in patients with NSTE ACS who all were scheduled for
angiography within 48 hours.
Patients and Methods
Consecutive patients with NSTE ACS were enrolled in the ELISA-2 trial. Inclusion
criteria were ischemic chest pain classified as Braunwald class 3 and the
presence of at least 1 of the following criteria: new ST depression of more than 1
mm in at least 2 ECG leads or a positive biomarker (cardiac troponin T > 0.05
µg/L, or CK-MB elevation more than upper limit of normal). Patients were
excluded for the following reasons: age > 80, persistent ST segment elevation,
previous percutaneous coronary intervention (PCI) within the preceding 6 months,
cardiogenic shock or a contra-indication for the use of triple antiplatelet therapy or
invasive therapy. All patients were treated with low molecular weight heparin, beta
blockers, statins, nitroglycerin and ACE inhibition when appropriate. After the
patients gave written informed consent they were randomized by a computerised
randomisation procedure. Patients were randomised to either pre-treatment with
dual (aspirin, clopidogrel 600 mg) or triple antiplatelet therapy (aspirin, clopidogrel
300 mg and tirofiban 10 microgram/kg bolus, 0.15 microgram/kg/min
maintenance) (Figure 1). 
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Figure 1: Study flow chart
Study medication was given in an open label manner. All patients were scheduled
for coronary angiography within 48 hours after admission. Type of
revascularisation, PCI or coronary artery bypass grafting (CABG), was left at the
discretion of the operator. In the triple antiplatelet group, tirofiban was continued
for 12 hours in case PCI was performed.  
Upstream tirofiban bailout in the dual antiplatelet patients was defined as,
initiation of tirofiban because of recurrent or persistent ischemia before
angiography. The bailout use of tirofiban downstream was left at the discretion of
the operator. Event free survival was defined as freedom of death or myocardial
infarction. The primary end point was enzymatic infarct size. Initial TIMI flow of the
culprit vessel was a pre-specified secondary end point. Both end points were
LMWH, Beta-Blocker and Statin
Randomization N =328
Dual antiplatelet
 (aspirin, clopidogrel 600 mg)
N= 166
Did not receive allocated treatment N = 3
Triple antiplatelet
(aspirin, clopidogrel 300 mg, tirofiban)
N= 162
Did not receive allocated treatment N= 0
Angiography N= 162
12-48 hours later
Assessed for eligibility N =448
NSTE ACS
Chest pain and elevated biomarkers or ST deviation
Excluded N = 120
Not meeting inclusion criteria or
refused participation
Angiography N = 159
Enzymatic infarct size analyzed N = 129
Not analyzed N = 37
Early discharge N= 21
No CAD N = 9
Not measured N= 7
Enzymatic infarct size analyzed N= 127
Not analyzed N = 35
Early discharge N= 13
No CAD N= 13
Not measured N= 9
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analyzed by an independent core lab (Diagram B.V., Zwolle, The Netherlands) by
technicians who were unaware of the clinical data. 
Enzyme Release and Enzymatic Infarct size
Blood samples were obtained on admission and every 6-12 hours hereafter up to
72 hours. In case PCI was performed later than 72 hours after admission, cardiac
enzymes were measured at 6 and 12 hours after PCI. Enzymatic infarct size
(LDHQ48) was calculated based upon enzyme concentrations of Lactate
Dehydrogenase (LDH) as the reference enzyme, in which an area under the
curve was calculated from at least 5 measurements. A two-compartment model
was used, which has been validated in studies on the turnover of radio labeled
plasma proteins and circulating enzymes [8-10]. In addition, as an alternative
assessment of enzymatic infarct size, peak creatin kinase (CK) was defined as
the highest level of CK during admission, with the exception of patients who
underwent CABG during the index hospital admission. 
Angiographic data analysis
All angiograms were analyzed by an independent core lab without knowledge of
clinical data. TIMI flow grades of the culprit vessel were assessed before and
after the angioplasty procedure, as previously described [11]. 
Clinical Outcome  
Total death and myocardial infarction were assessed at 30 day follow-up.
Myocardial infarction was defined as a CK-MB elevation of more than 6% of total
CK, whenever CK was above 200 U/l (men) or above 170 U/l (women). After
CABG, myocardial infarction was defined as the development of new Q waves on
the post CABG electrocardiogram. Major bleeding was defined as the need for at
least 2 units of blood and a fall in haemoglobin of more than 2 mmol/l, corrective




Sample size calculation was made based on the findings of ELISA-1 trial [7]. Our
hypothesis was that a strategy of triple anti platelet therapy would reduce
enzymatic infarct size by 30%. It was calculated, assuming an infarct size of 500
IU/l for the dual and 350 IU/l for the triple antiplatelet group with a standard
deviation of 500 and assuming normal distribution of enzymatic infarct size, that
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330 patients were needed to prove superiority of triple over dual anti-platelet
therapy with a power of 80% and assuming a type I error of 5%. 
Final Analysis
The primary end point was compared using the Mann Whitney test and expressed
as median and 25 -75 percentiles. The secondary end point, initial TIMI 3 flow of
the culprit vessel, was compared using Chi square analysis. The Fisher’s exact
test was used when the expected cell value was < 5. Data were analysed
according to the intention to treat principle. The difference in the occurrence of
death or myocardial infarction between the groups during 30 day follow-up was
assessed by the Kaplan-Meier method using the log-rank test. A p value < 0.05
was considered statistically significant. All tests were two-sided.
Results
From September 2002 to January 2005, 328 patients were included, 166 were
randomised to dual, 162 to triple antiplatelet therapy. Baseline characteristics
were not different between the groups (Table 1), except for a higher age in the
dual antiplatelet group (65 vs. 62 years, P=0.008). Seventy eight percent of
patients had a positive troponin T at the time of inclusion and 61% had at least 1
mm of ST depression at electrocardiography on admission. Angiography was
performed in 98% of patients after a median of 23 hours after admission, without
a difference between the groups (P = 0.9). 
Primary and secondary end points
Enzymatic infarct size as assessed by LDHQ48 or Peak CK is shown in Table 2
and Figure 2 and could be assessed in 256 (78%) and 327 (99,9%) patients,
respectively. LDHQ48 median was 166 in the triple vs. 193 IU/l in the group who
received dual pre-treatment, (relative reduction (RR): 14%, p=0.2). Peak CK was
216 IU/l in the triple antiplatelet group and 261 IU/l in the dual antiplatelet group
(RR 17%, p=0.3). 
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Table 1: Baseline and angiographic data
Dual Triple
Variable                                              (n= 166)                                  (n= 162)                 P-value
Age (yrs ± SD) 65 ± 10 62 ± 11 0.008
Female Gender, n (%) 46 (28) 49 (30) 0.6
Diabetes Mellitus, n (%) 33/165 (20) 24/159 (15) 0.2
Hypertension, n (%) 81/159 (51) 70/151 (46) 0.4
Smoking, n (%) 64/146 (44) 59/146 (40) 0.6
Hypercholesterolemia, n (%) 62/143 (43) 53/137 (39) 0.4
Previous MI, n (%) 33/166 (20) 36/162 (22) 0.6
Previous PCI, n (%) 30/166 (18)  35/162 (22) 0.4
Previous CABG, n (%) 26/166 (16) 16/162 (10) 0.1
Symptom onset- admission 2.9 (1.8-5.5)   2.6 (1.6-6.8) 0.7 
Median (25-75 percentile)(hrs)  
Admission – angio   22.5 (15.1-30)  22.2 (15.3-29) 0.3
Median (25-75 percentile)(hrs)  
Urgent angio, n (%) 32/159 (20)  28/152 (18) 0.7
Syst BP (mmHg)  149 ± 27 144 ± 24 0.1
Troponin T> 0.05 ng/ml n, %  115 (71) 98 (63) 0.1
TIMI risk score, mean ± SD 2.9 ± 1.4 2.9 ± 1.3 0.8
ST depression > 1 mm, n, %             99 (61)                                    99(62)                         0.9
MI= myocardial infarction, PCI= percutaneous coronary intervention, CABG= coronary artery bypass
grafting, Syst BP= systolic blood pressure
Table 2:  Enzyme release 
Dual Triple
Variable                                  (n= 166)                                  (n= 162)                 P-value    
Peak CK (IU/L)  261 (114 – 508 )     216 (93 – 480) 0.3
Peak CK-MB (IU/L)  33 (19 – 70)  27 (17.5 – 55) 0.2
LDHQ48 (IU/L)                       193 (75-466)                           166 (60-349)               0.2       
CK= creatine kinase, CK-MB= creatine kinase MB mass, LDHQ48 = Enzymatic infarct size (area under
the lactate dehydrogenase release over 48h curve) Data are expressed as median and 25-75
percentiles
Table 3 shows the angiographic parameters. Initial TIMI flow could be assessed
in 248 out of 281 (86%) patients with a confirmed diagnosis of an acute coronary
syndrome. Initial TIMI 3 flow of the culprit vessel was present in 67 % in the triple
antiplatelet group, as compared to 47% in the dual antiplatelet group (P = 0.002).
At initial angiography, thrombus was present in 6% in the triple antiplatelet group
compared to 11% in the dual antiplatelet group (p = 0.1).  
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Figire 2: Enzymatic infarct size
Table 3: Angiography
Dual Triple
Variable                                              (n= 166)                                  (n= 162)                  P-value
Angio performed, n (%) 162 (98)  159 (98) 1.0
Number of vessel disease, n (%)  
0  17/162 (11)  23/159(15) 0.3
1   54/162 (33)  55/159(34) 0.8
Multi vessel  89/162 (55) 78/162 (49) 0.3
Left main  2/162 (1)  3/159(2) 0.7
TIMI flow culprit pre, n (%)   
3  62/131 (47)  79/118 (67) 0.002
0-2 69/131 (53) 39/118 (33)
Thrombus initial angio  16/145 (11) 8/135 (6) 0.1
Indication, n (%) 
Conservative no vessel disease  17/162 (10)  23/159 (14)  0.3
    Conservative  21/162 (13)  19/159 (12) 0.8
    PCI  100/162 (62)  89/159 (56)  0.3
    CABG  24/162 (15)  28/159 (18)  0.5
   Stenting  86/100 (86)  71/86 (83)  0.5
TIMI flow post, n (%)  
0-2 9/100 (9) 3/86 (4) 0.1
            3                                              91/100 (91)                             83/86 (97)                   0.1
TIMI = Thrombolysis in Myocardial Infarction, PCI = percutaneous coronary intervention,
CABG= coronary artery bypass grafting
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After multivariate analysis, correcting for all parameters which were borderline
different (P<0.10) between the 2 groups (table 1), the results of the primary and
secondary end point did not change, no significant effect was found on enzymatic
infarct size, OR: 0.85: 95% CI: 0.52-1.40; P = 0.6, however triple antiplatelet pre-
treatment remained independently associated with a higher initial patency of the
culprit lesion, OR: 2.5, 95% CI: 1.5-4.4; P = 0.001. Percutaneous coronary
intervention and CABG were performed equally in both groups. TIMI 3 flow after
PCI was 97% vs. 91% in the triple and dual antiplatelet group, respectively (p =
0.10). 
Bail-out use of tirofiban
Bail-out tirofiban was used in 37 patients (22%) allocated to the dual antiplatelet
group. In 8 patients (5%) upstream tirofiban was given because of persistent
symptoms of ischemia before angiography. Another 29 patients (17%) were
treated with tirofiban after angiography or PCI (downstream). 
Medication
On discharge the fast majority of the patients received aspirin, beta blockers,
statins and clopidogrel (Table 4).
Table 4: Discharge medication
Dual Triple
Variable                                              (n= 162)                      (n= 159)                   P-value    
Aspirin, n (%) 140 (86) 143 (90) 0.3
Beta-Blocker, n (%)                             138 (85) 137 (86) 0.8
Statin, n (%)                                        134 (83) 119 (75) 0.08
Clopidogrel, n (%)                               108 (67)   100 (63) 0.5
ACE inhibitor, n (%)                             66 (41) 57 (36) 0.4
Diuretics, n (%)                                    20 (12) 22 (14) 0.7
Oral anti-coagulation                           13 (8)                        13 (8)                          1.0       
Clinical outcome
Table 5 shows 30 day outcomes. Thirty day follow up was available in 325 (99%)
of patients. Death or myocardial infarction at 30 day follow-up occurred in 46% of
patients in the triple antiplatelet group, as compared to 59% in the dual
antiplatelet group (p=0.052) (Figure 3) according to the intention to treat analysis.
Whether myocardial infarction was present on admission or occurred later as
evolving or peri-procedural is given in Table 5 as well. Three patients had a




Table 5: Patient outcomes at 30-day
Dual Triple
Variable                                              (n= 163)                      (n= 162)                   P-value  
Death, n (%) 1 (1)  1 (1)  1.0
Infarction, n (%) 93 (57) 75 (46) 0.052
Admission 42(26) 33(20)
Evolving 40 (25) 33(20)
Peri-PCI 11(7) 7 (4)
Re-infarction 1(1) 2(1)
Death or infarction, n (%) 93 (57)  75 (46)  0.052
Stroke, n 0 0 1.0   
Bleeding, n (%) 16 (10) 20 (12) 0.5
CABG related, n (%) 10 (6) 14 (9) 0.69
           Surgical re-exploration           2 (20)                          4 (29)                          1.0       
P = 0.098


























Sixteen patients (10%) in the dual group and twenty patients (12%) in the triple
group had major bleeding complication (P = 0.5). CABG related bleeding occurred
in 10 and 14 patients, respectively. Six patients underwent surgical re-exploration
because of tamponade. Intracranial haemorrhage did not occur in either
treatment.
Discussion
This is the first study that compared an oral antiplatelet drug regimen of aspirin
and high dose clopidogrel to a drug regimen containing aspirin, clopidogrel and
intravenous tirofiban as upstream therapy in patients with non ST segment
elevation acute coronary syndrome, who were all scheduled for early
angiography. Only a small, non-significant decrease of enzymatic infarct size
(primary endpoint) was observed after triple antiplatelet therapy. However, initial
TIMI 3 flow of the culprit vessel, a pre-specified secondary end point, was also
more often present in patients pre-treated with the triple antiplatelet regimen.
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Figure 3B: 30-day event free survival
ELISA-2 trial
72
This is in accordance with the findings of the ELISA-1 study [7] and the PRISM
plus angiographic sub study [12] which found a better initial perfusion and a lower
presence of thrombus of the culprit vessel in patients pre-treated with tirofiban as
compared to no tirofiban. In the latter study, the difference in angiographic
outcome closely paralleled differences in clinical outcome.
The beneficial value of upstream use of glycoprotein IIb/IIIa inhibitors on reduction
of thrombus and improvement of initial patency has been described earlier,
however, it is questionable whether the improved angiographic outcome pre-PCI
translates into a better outcome after PCI. A TACTICS-TIMI 18 sub study showed
that longer pre-treatment with tirofiban was associated with improved pre- and
post-PCI myocardial perfusion [13]. Also the PRISM plus angiographic sub study
found that initial TIMI 3 flow was associated with a better post-PCI TIMI flow [12].
In our study, there was a trend towards a better post-PCI TIMI flow in patients
treated with triple antiplatelet pre-treatment. 
Enzymatic infarct size in NSTE ACS
In patients with NSTE ACS, changing the definition of myocardial infarction may
have important consequences. This was recently shown in the ICTUS trial, where
outcome was different when the TACTICS criteria for myocardial infarction were
used [14]. In our study however, outcome did not change when the 3 times upper
limit of normal value was used as cut-off. In Table 5, myocardial infarction is given
depending on the time of occurrence. Evolving myocardial infarction tended to
occur less often in the patients allocated to triple antiplatelet pre-treatment,
however, peri-procedural infarction may be masked by the presenting acute
coronary syndrome, especially when PCI is performed very early after admission.
This is why we chose enzymatic infarct size over a period of time. This takes total
enzyme release over a period of time into account and may better quantify the
effect of distal micro-embolization, especially in patients whose enzymes have not
returned to normal values on the moment of intervention. Elisa-1 showed that by
using total enzyme release over a period of time, it was possible to detect an
effect of treatment, which not became evident when the incidence of (recurrent)
myocardial infarction was assessed only [7]. Previous studies which also
evaluated enzymatic infarct size in patients with NSTE ACS found that enzymatic
infarct size well correlated with clinical outcome [15].
Comparison with other studies
In previous studies which compared dual with triple antiplatelet pre-treatment,
patients with acute coronary syndromes were excluded. The ISAR-REACT trial
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performed in patients undergoing elective PCI, did not find a difference in
outcome between the groups [16]. The CLEAR PLATELETS study showed that,
in elective stenting, use of a GP IIb/IIIa inhibitor on top of clopidogrel produced
superior platelet inhibition and lower myocardial necrosis compared with high-
dose (600 mg) or standard-dose (300 mg) clopidogrel alone [17]. In our study, in
patients with non STE ACS, the addition of tirofiban to aspirin and clopidogrel was
associated with a non significant trend towards a better outcome and a beneficial
effect on angiographic outcome. However, due to the small sample size of the
trial, it is not possible to draw definite conclusions from our study. With the
present level and difference of enzymatic infarct size between the groups, around
2.310 patients would have been needed to demonstrate a significant difference.
The ongoing early ACS study, with a comparable design as ELISA-2, has planned
to include more than 10.000 patients, to find a difference in a combined clinical
end point [18]. Therefore, according to these results, there is no reason to change
the most recent guidelines on PCI which recommend both clopidogrel 600 mg
and a glycoprotein IIb/IIIa inhibitor in high risk patients with ACS undergoing PCI
[19].
Safety 
No significant difference in bleeding was observed between the 2 groups and
intracranial haemorrhage did not occur in either treatment. However, among
CABG treated patients 10 out of 24 in the dual and 14 out of 28 in the triple
antiplatelet treated patients had procedural bleedings. In 18 patients a fall in
haemoglobin of more than 2 mmol/l requiring blood transfusion was present. In 6
patients, surgical re-exploration was performed because of pericardial
tamponade. Despite this relatively high incidence of bleeding, clinical outcome
was good in the patients who underwent CABG. So far, there are no large trials
with concomitant use of GP IIb/IIIa inhibitor and high dose clopidogrel in NSTE
ACS patients. The ISAR-REACT trial [16], in patients undergoing elective PCI
showed no difference in major or minor bleeding, however, the incidence of minor
bleeding complications, i.e. thrombocytopenia and the transfusion of blood
products, was higher in the triple group. Also the CLEAR PLATELETS study
showed no difference in bleedings complication between dual and triple
antiplatelet therapy [17]. To draw definitive conclusions on the safety of triple





The dose of clopidogrel in the triple antiplatelet group was 300 mg, compared to
600 mg in the dual group. The lower dose was chosen because no data existed
on the combination of intravenous tirofiban and 600 mg clopidogrel on a possible
higher risk of bleeding at the moment the study was designed in 2001. However
Gurbel et al17 found that platelet inhibition dose not differ when a glycoprotein
IIb/IIIa inhibitor is combined with either 600 mg or 300 mg clopidogrel. Another
limitation of the study is that LDHQ48 is not an established end point in NSTE ACS
trials. However, previous trials showed that enzymatic infarct size is well
correlated with clinical parameters [15,20]. Furthermore, in this study there was a
slight difference in baseline characteristics, however, after performing a
multivariate analysis correcting for the borderline differences between the two
groups (P<0.10), the results of primary and secondary endpoints did not change.
Finally, enzymatic infarct size was not calculated in 22% of the patients (Figure
1), however in these patients median CK’s were not different between the two
groups, (135 (80-269) and 124 (71-226) in the dual and triple group, respectively).
Conclusion
This study showed that in patients with NSTE ACS, triple antiplatelet therapy was
associated with a non-significant reduction in enzymatic infarct size, a significantly
better initial perfusion of the culprit vessel and a trend towards a better survival
without death or myocardial infarction. This study supports the current guideline18
that recommend use of both clopidogrel and a GP IIb/IIIa inhibitor in high risk
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